“RNA Interference (RNAi) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the RNA Interference Market.
The RNA Interference Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
RNA Interference Pipeline Analysis
The report provides insights into:
The report provides detailed insights into emerging therapies in the RNA Interference Market and the aggregate therapies developed by major pharma companies.
It accesses the different RNA Interference therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development.
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the RNA Interference Market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Delveinsight’s Report Covers Around 90+ Products Under Different Phases of Clinical Development Like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Learn More About the Ongoing Clinical & Commercial Activities in the RNA Interference Therapeutic Market @
https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight
RNA Interference Therapeutics Landscape
There are approx. 20+ key companies developing therapies based on RNA Interference. Currently, Alnylam Pharmaceuticals has its RNA Interference drug candidates in the most advanced stage of clinical development.
Some of the Companies Developing the RNA Interference Based Therapies in the Market Include:
Alnylam Pharmaceuticals
Suzhou Ribo Life Science
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Sylentis
Vir Biotechnology
Arbutus Biopharma
Silenseed
OliX Pharmaceuticals
Bio-Path Holdings
Janssen Pharmaceuticals
Eli Lilly and Company
Amgen
Sirnaomics
Silence Therapeutics
Phio Pharmaceuticals
Medesis Pharma
Atalanta Therapeutics
Mirimus/ Biogen
Mallinckrodt/Silence Therapeutics
And many others
RNA Interference Emerging Drugs Covered and Analyzed in the Report Include:
Vutrisiran: Alnylam Pharmaceuticals
Cemdisiran: Alnylam Pharmaceuticals
SR061: Suzhou Ribo Life Science
ARO-APOC3: Arrowhead Pharmaceuticals
DCR-PHXC: Dicerna Pharmaceuticals
And many more
Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. RNA Interference Current Treatment Patterns
4. RNA Interference – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. RNA Interference Late Stage Products (Phase-III)
7. RNA Interference Mid-Stage Products (Phase-II)
8. RNA Interference Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. RNA Interference Discontinued Products
13. RNA Interference Product Profiles
14. Key Companies in the RNA Interference Market
15. Key Products in the RNA Interference Therapeutics Segment
16. Dormant and Discontinued Products
17. RNA Interference Unmet Needs
18. RNA Interference Future Perspectives
19. RNA Interference Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
